

IMMUcan samples available per cohort – October 2025

NSCLC-samples available at IBBL (cut off 14/10/2025)

NSCLC: 232 patients enrolled

sample type	Registration	progression	Other-TBC	Grand Total
genomicDNA	223	35	5	263
Paraffin_Block-TIS*	175	2	1	178
PAX	209	42	6	257
PBMC_viable	171	37	5	213
Plasma from EDTA	190	42	4	236
Plasma from SCK	189	21	4	214
SER	192	42	4	238
<i>leftover after analysis-gDNA</i>	214		4	218
<i>leftover after analysis-tumorDNA</i>	188	3	1	192
<i>leftover after analysis-tumorRNA</i>	197	2	2	201

*minimal material available 20µm (5 slides of 4µm)

Breast Cohort 1-sample available at IBBL (cut off 14/10/2025)

BC1: 36 patients enrolled

sample type	Registration	Progression	Other TBC	Grand Total
genomicDNA	34	2	4	40
Paraffin_Block-TIS*	19	3		22
PAX	36	6	2	44
PBMC_viable	31	6	3	40
Plasma from EDTA	36	7	4	47
Plasma from SCK	34	5	4	43
SER	35	7	4	46
<i>leftover after analysis-gDNA</i>	35		1	36
<i>leftover after analysis-tumorDNA</i>	32	3	2	37
<i>leftover after analysis-tumorRNA</i>	33	3	2	38

*minimal material available 20µm (5 slides of 4µm)

Breast Cohort 2-sample available at IBBL (cut off 14/10/2025)

BC2: 408 patients enrolled

sample type	Registration	Surgery	Other TBC	Grand Total
genomicDNA	399		3	403
Paraffin_Block-TIS*	274	12		286
PAX	94		3	97
PBMC_viable	321		2	323
Plasma from EDTA	387		3	390
Plasma from SCK	399		3	402
SER	382		3	385
<i>leftover after analysis-gDNA</i>	404		2	406
<i>leftover after analysis-tumorDNA</i>	372	48		420
<i>leftover after analysis-tumorRNA</i>	379	50		429

*minimal material available 20µm (5 slides of 4µm)

Breast Cohort 3-sample available at IBBL (cut off 14/10/2025)

BC3: 331 patients enrolled

sample type	Registration	Surgery	other TBC	Grand Total
genomicDNA	320		2	322
Paraffin_Block-TIS*	253	10		263
PAX	294		2	296
PBMC_viable	264		2	266
Plasma from EDTA	296		2	298
Plasma from SCK	321		2	323
SER	297		2	299
<i>leftover after analysis-gDNA</i>	325		1	326
<i>leftover after analysis-tumorDNA</i>	301	41		342
<i>leftover after analysis-tumorRNA</i>	307	41		348

*minimal material available 20µm (5 slides of 4µm)

RCC-samples available at IBBL (cut off 14/10/2025)

RCC: 106 patients enrolled				
sample type	Registration	Progression	Other- TBC	Grand Total
genomicDNA	103	9	3	115
Paraffin_Block-TIS*	62	1	1	64
PAX	94	10	6	110
PBMC_viable	82	8	6	96
Plasma from EDTA	99	10	7	116
Plasma from SCK	94	4	3	101
SER	98	10	7	115
<i>leftover after analysis-gDNA</i>	103			103
<i>leftover after analysis-tumorDNA</i>	92		1	93
<i>leftover after analysis-tumorRNA</i>	50		1	51

*minimal material available 20µm (5 slides of 4µm)

mCRC-samples available at IBBL (cut off 14/10/2025)

mCRC: 84 patients enrolled		
sample type	Registration	pairs primary-m
genomicDNA	85	
Paraffin_Block-TIS*	56	26
PAX	79	
PBMC_viable	72	
Plasma from EDTA	73	
Plasma from SCK	84	
SER	72	
<i>leftover after analysis-gDNA</i>	83	
<i>leftover after analysis-tumorDNA</i>	0	0
<i>leftover after analysis-tumorRNA</i>	160	78

*minimal material available 20µm (5 slides of 4µm)

HN1-samples available at IBBL (cut off 14/10/2025)

H&N cohort 1: 253 patients
entolled

sample type	Registration	Progression	Other-TBC	Grand Total
genomicDNA	240	22	11	273
Paraffin_Block-TIS*	103	3	1	107
PAX	159	40	13	212
PBMC_viable	189	38	2	239
Plasma from EDTA	228	47	4	289
Plasma from SCK	193	14	6	213
SER	228	47	14	289
<i>leftover after analysis-gDNA</i>	249		2	251
<i>leftover after analysis-tumorDNA</i>	45	7	1	53
<i>leftover after analysis-tumorRNA</i>	46	8	1	55

*minimal material available 20µm (5 slides of 4µm)

HN2-samples available at IBBL (cut off 14/10/2025)

H&N cohort 2: 10 patients entolled

sample type	Registration	pairs registration-local recurrence
genomicDNA	10	
Paraffin_Block-TIS*	14	7
PAX	9	
PBMC_viable	8	
Plasma from EDTA	10	
Plasma from SCK	9	
SER	10	
<i>leftover after analysis-gDNA</i>	10	
<i>leftover after analysis-tumorDNA</i>	8	3
<i>leftover after analysis-tumorRNA</i>	7	3

*minimal material available 20µm (5 slides of 4µm)

Summary overview FFPE blocks -cut off 14/10/2025

Row Labels	Progression	Other-TBC	Registration	Surgery	Grand Total
Breast Cohort 1		3		19	22
Breast Cohort 2				274	286
Breast Cohort 3				253	263
mCRC Cohort				56	56
HNSCC Cohort 1		3	1	103	107
HNSCC Cohort 2				14	14
NSCLC		2	1	175	178
RCC		1	1	62	64
Grand Total		9	3	956	990